InsidersTradesSigma
Total declarations
Company
▲ Purchases (20 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
20
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
+3.8%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Weisblum Eric, Chief Executive Officer. Officer active across 1 company, notably Silo Pharma, Inc.. Aggregated, 22 filings have been logged. Breakdown: 20 buys · 0 sell. Total volume traded: €33k. Activity tracked since 17 June 2019. The latest transaction was disclosed on 13 December 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations22 total
2,500 shares@ US$0.83876.1% of flowCommon StockSEC:0001213900-24-109363:0
Ideal exit: 9 Sept 2025 (T+270)
2,500 shares@ US$0.956.8% of flowCommon StockSEC:0001213900-24-101610:0
Ideal exit: 17 Aug 2025 (T+270)
562 shares@ US$1.081.7% of flowCommon StockSEC:0001213900-24-052354:0
Ideal exit: 8 Mar 2025 (T+270)
600 shares@ US$1.963.3% of flowCommon StockSEC:0001213900-24-031159:0
Ideal exit: 30 Dec 2024 (T+270)
3,408 shares@ US$1.9418.6% of flowCommon StockSEC:0001213900-24-028973:0
Ideal exit: 23 Dec 2024 (T+270)
500 shares@ US$1.632.3% of flowCommon StockSEC:0001213900-23-097689:0
Ideal exit: 14 Sept 2024 (T+270)
200 shares@ US$1.500.8% of flowCommon StockSEC:0001213900-23-096606:0
Ideal exit: 9 Sept 2024 (T+270)
600 shares@ US$1.392.3% of flowCommon StockSEC:0001213900-23-094145:0
Ideal exit: 31 Aug 2024 (T+270)
1,000 shares@ US$1.574.3% of flowCommon StockSEC:0001213900-23-091665:0
Ideal exit: 25 Aug 2024 (T+270)
400 shares@ US$1.681.9% of flowCommon StockSEC:0001213900-23-090270:0
Ideal exit: 18 Aug 2024 (T+270)
4,050 shares@ US$1.6018.1% of flowCommon StockSEC:0001213900-23-089570:0
Ideal exit: 16 Aug 2024 (T+270)
1,100 shares@ US$1.334.1% of flowCommon StockSEC:0001213900-23-088890:0
Ideal exit: 12 Aug 2024 (T+270)
2,500 shares@ US$2.0614.5% of flowCommon StockSEC:0001213900-23-041179:0
Ideal exit: 11 Feb 2024 (T+270)
200 shares@ US$2.68151.5% of flowCommon StockSEC:0001213900-22-081513:0
Ideal exit: 15 Sept 2023 (T+270)
487 shares@ US$3.06764.3% of flowCommon StockSEC:0001213900-22-080102:0
Ideal exit: 9 Sept 2023 (T+270)
13,080 shares@ US$0.11470.022% mcap47.4% of flowCommon StockSEC:0001213900-22-033752:0
Ideal exit: 14 Mar 2023 (T+270)
5,000 shares@ US$0.155487.0% of flowCommon StockSEC:0001213900-21-065395
Ideal exit: 6 Sept 2022 (T+270)
5,000 shares@ US$0.15540.011% mcap22.9% of flowCommon StockSEC:0001213900-21-065395:0
Ideal exit: 6 Sept 2022 (T+270)
7,630,949 sharesCommon StockSEC:0001213900-21-026677
7,630,949 sharesCommon StockSEC:0001213900-21-026677:0
57,714 shares@ US$0.0020.0016% mcap3.4% of flowCommon StockSEC:0001213900-21-026675:0
Ideal exit: 13 Mar 2020 (T+270)
57,714 shares@ US$0.0023.4% of flowCommon StockSEC:0001213900-21-026675
Ideal exit: 13 Mar 2020 (T+270)
22 of 22 declarations
About Weisblum Eric
Eric Weisblum serves as the Chief Executive Officer, Chief Financial Officer, and President of Silo Pharma, Inc. He oversees the company's operations and is responsible for financial management. His leadership is essential for the success of the organization.
